Safety and tolerability of antipsychotic polypharmacy.

Expert Opinion on Drug Safety
Juan A GallegoChristoph U Correll

Abstract

Antipsychotic polypharmacy (APP), the concomitant use of ≥ 2 antipsychotics, is common in clinical practice. Prior reviews have focused on the efficacy of APP, but no systematic review exists regarding the safety and tolerability of this practice. A systematic review of adverse effects associated with APP was conducted to prepare this review; case series with ≥ 2 patients, chart reviews, naturalistic, database, cohort and randomized studies that reported on the association between APP in general or specific APP combinations and global or specific adverse effect were included. Methodological limitations of available studies are discussed and recommendations for clinicians and future research are provided. Across mostly small and uncontrolled studies, APP has been associated with increased global side effect burden, rates of Parkinsonian side effects, anticholinergic use, hyperprolactinemia, sexual dysfunction, hypersalivation, sedation/somnolence, cognitive impairment and diabetes. Effects on akathisia and mortality were inconclusive. Although some combinations, particularly aripiprazole augmentation of an agent with greater side effect burden, may reduce weight gain, dyslipidemia, hyperprolactinemia and sexual dysfunction, APP ...Continue Reading

References

Jan 1, 1986·Psychopharmacology·N M RupniakC D Marsden
Jan 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·A F Clark, N L Holden
Nov 1, 1995·British Journal of Clinical Pharmacology·R A KiivetF Sjöqvist
Aug 1, 1997·Journal of Clinical Psychopharmacology·M HummerW W Fleischhacker
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·R ShilohA Weizman
Feb 2, 1999·The British Journal of Psychiatry : the Journal of Mental Science·J L WaddingtonA Kinsella
Apr 6, 1999·Schizophrenia Research·R G Petty
Jan 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·C H Miller, W W Fleischhacker
Jun 14, 2000·The Annals of Pharmacotherapy·L Davydov, S R Botts
Sep 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·N A Buckley, P Sanders
Jun 5, 2001·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R M ProcyshynB Thompson
Sep 20, 2001·The Journal of Clinical Psychiatry·D C HendersonD Hayden
Mar 5, 2002·The Journal of Clinical Psychiatry·Stephen M Stahl
Jan 25, 2003·Journal of Clinical Psychopharmacology·Cristóbal GastóMiquel Rodamilans
Mar 4, 2003·The British Journal of Psychiatry : the Journal of Mental Science·A Wieck, P M Haddad
Jul 2, 2003·Journal of Clinical Psychopharmacology·Norman Sussman
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Takefumi SuzukiHaruo Kashima
Apr 2, 2004·The American Journal of Psychiatry·Franca CentorrinoRoss J Baldessarini
Jul 17, 2004·British Journal of Clinical Pharmacology·Kang SimChay H Tan
Aug 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·David TaylorRebecca Walwyn
Sep 4, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Leslie CitromeJames Robinson
Nov 24, 2004·The Journal of Clinical Psychiatry·Julie MontgomeryRichard C Josiassen
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 22, 2005·Clinical Neuropharmacology·Marc ZiegenbeinHeike E Kuenzel
Jan 21, 2006·Acta Psychiatrica Scandinavica·R M CarnahanE A Chrischilles
Feb 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Matti JoukamaaVille Lehtinen
Feb 3, 2006·The New England Journal of Medicine·William G HonerUNKNOWN Clozapine and Risperidone Enhancement (CARE) Study Group
Mar 3, 2006·Toxicology and Applied Pharmacology·Zaheed HusainEdmond J Yunis
May 2, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Fábio Lopes Rocha, Cláudia Hara
Jun 1, 2006·Clinical Practice and Epidemiology in Mental Health : CP & EMH·L HanssensJ Peuskens
Jun 24, 2006·Schizophrenia Research·Hiroaki HoriHiroshi Kunugi
Jul 28, 2006·Psychiatric Services : a Journal of the American Psychiatric Association·Miranda H ChakosRobert A Rosenheck
Oct 3, 2006·International Clinical Psychopharmacology·Corrado BarbuiMichele Tansella
Oct 20, 2006·Journal of Psychopharmacology·Kanapathippillai KarunakaranGiles C Harborne
Oct 31, 2006·Schizophrenia Research·Christoph U CorrellPeter Manu
Feb 7, 2007·Current Opinion in Psychiatry·Peter Malik
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Sangwon F KimSolomon H Snyder
Apr 7, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Julie A KreyenbuhlFrederic C Blow
Apr 21, 2007·Psychiatry Research·Marc De HertJozef Peuskens

❮ Previous
Next ❯

Citations

Feb 14, 2013·Current Psychiatry Reports·Ursula WernekeThomas A B Sanders
Apr 23, 2013·Psychiatry Research·Taishiro KishimotoChristoph U Correll
Jan 16, 2013·Current Opinion in Psychiatry·Jacob Ballon, T Scott Stroup
Apr 10, 2014·Evidence-based Mental Health·Markus Dold, Stefan Leucht
Feb 25, 2014·Social Psychiatry and Psychiatric Epidemiology·Anthony P Polednak
Jan 31, 2016·European Journal of Pharmacology·Pawel MierzejewskiPrzemyslaw Bienkowski
Aug 30, 2012·The Psychiatric Clinics of North America·Christoph U Correll, Juan A Gallego
Sep 6, 2013·Acta Psychiatrica Scandinavica·S GeeD Taylor
Feb 13, 2016·International Clinical Psychopharmacology·Niklas SchmedtEdeltraut Garbe
Oct 16, 2015·Journal of Child and Adolescent Psychopharmacology·Logan K WinkCraig A Erickson
Aug 11, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Benjamin SneiderJimmi Nielsen
Mar 5, 2016·Expert Opinion on Drug Safety·Christoffer PolcwiartekJimmi Nielsen
May 29, 2015·Acta Psychiatrica Scandinavica·P ManuC U Correll
Apr 2, 2016·Journal of Clinical Psychopharmacology·Katherine W ScangosWilliam J Newman
Mar 17, 2016·Journal of Clinical Psychopharmacology·John C HammondNina V Kraguljac
Mar 3, 2015·European Psychiatry : the Journal of the Association of European Psychiatrists·W GaebelUNKNOWN European Psychiatric Association
Feb 14, 2015·Journal of Clinical Psychopharmacology·Alexander Panickacheril John, Milan Dragovic
May 16, 2013·The International Journal of Neuropsychopharmacology·Nitin TotejaChristoph U Correll
Sep 15, 2016·Acta Psychiatrica Scandinavica·K JobskiC Bachmann
Jul 23, 2013·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Licia Maiocchi, Elsa Bernardi
Apr 30, 2017·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Masakazu HatanoNakao Iwata
Oct 19, 2016·The Journal of ECT·Qian LiTian-Mei Si
Feb 22, 2017·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Yu-Tao XiangNaotaka Shinfuku
May 15, 2013·The Australian and New Zealand Journal of Psychiatry·Daeyoung RohYoung-Chul Jung
Nov 11, 2017·International Psychogeriatrics·Lisa M Kalisch EllettElizabeth E Roughead
Nov 30, 2018·PloS One·Paul M BakakiLawrence C Kleinman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.